SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs upcoming Phase 3 REGAL trial results for its GPS leukemia treatment dominate discussion, with topline data expected this month after the trial reached its final analysis milestone. Traders are split between optimism about a potential breakthrough and concern over the binary trial outcome, while sharp price swings have fueled debate about selling pressure and alleged short-term manipulation.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summits FDA review of ivonescimab for EGFR-mutated lung cancer is driving a binary-outcome debate over approval versus a possible rejection or request for more evidence. Bulls point to strong progression-free-survival results and encouraging survival trends, while bears focus on the FDAs stated need for statistically significant overall-survival evidence; recent weakness has also prompted speculation about a negative outcome, though traders say price action alone is not proof.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian shares are under pressure amid a broader pullback in EV and growth stocks, with traders also focused on the stocks persistent weakness and concerns about cash burn, profitability, and management. Some blame short sellers or trading dynamics, while bulls point to R2 progress and recent operating results as reasons for optimism; those explanations remain debated.

Unity Software, Inc. engages in the developing video gaming software. It also provides software solutions to create, run and monetize interactive, real-time two-dimensional and three-dimensional content for mobile phones, tablets, consoles, and augmented and virtual reality devices. Its platform is used by developers, artists, and designers to build content for gaming, film, retail, automotive, architecture, engineering, and construction industries. The company was founded by Joachim Ante and David Helgason in 2004 and is headquartered in San Francisco, CA.

Unity Software Inc

Unitys strong Q3 resultsits first GAAP-profitable quarter, rapid growth in its Vector ad platform, and upbeat outlookhave fueled a sharp rebound and discussion of a possible turnaround. Reported takeover talks with Silver Lake and Saudi Arabias PIF add speculation, with traders debating whether the discussed valuation would undervalue the company or whether a deal will happen at all.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQs sharp after-hours drop drew attention as traders linked the move to the FAAs nationwide ground stop after communications problems, while speculation about a cyberattack or AI involvement remained unverified. The discussion also reflected wider pressure on tech and AI stocks tied to uncertainty around Nvidia, with traders divided between seeing the selloff as an overreaction and expecting further weakness.

American Airlines Group, Inc. is a holding company, which engages in the operation of a network carrier through its principal wholly owned mainline operating subsidiary, American. The firm offers air transportation for passengers and cargo. It operates through the following geographical segments: Domestic, Latin America, Atlantic, and Pacific. The company was founded on December 9, 2013, and is headquartered in Fort Worth, TX.

American Airlines Group Inc

Reports of an FAA nationwide ground stop tied to air-traffic-control communications problems are drawing attention to AAL, with traders discussing possible departure delays and rerouting. Some characterize the disruption as brief, while speculation about its cause remains unverified.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Jensen Huangs abrupt departure and the unresolved CEO succession are driving concern, with traders divided between those calling for his return and those worried about leadership continuity and scrutiny of Nvidias China-related chip sales. Upcoming earnings are another focus, but bullish bets on results and dip-buying compete with fears that uncertainty and further fallout could weigh on the stock.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is selling off after lowering its revenue outlook amid delays activating third-party data-center capacity, prompting analyst concerns about execution and near-term growth; weakness across AI and neocloud stocks, alongside uncertainty around Nvidia, is adding pressure. Traders are split between viewing the delays and higher spending as serious risks and seeing them as temporary setbacks in a business with strong AI demand.

RUM Group, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

RUM Group Inc. - Ordinary Shares - Class A

RUM Group Inc.

RUMs strong third-quarter results and rapid growth in its Quake AI GPU-cloud business are driving attention as the companys AI-infrastructure pivot gains traction. Bulls point to improving operations and the Anthropic-linked expansion, while skeptics focus on losses, cash needs and financing risks; short-squeeze claims remain speculation.

HawKeye 360, Inc. engages in the provision of defense technology. It offers spectrum monitoring, maritime intelligence, air defence radar monitoring, GNSS interference detection, and communications mapping. Its costumers include a wide range of commercial, government and international entities. The company was founded by Charles T. Clancy, Robert G. McGwier, Chris DeMay and John Serafini in 2015 and is headquartered in Herndon, VA.

HawkEye 360 Inc.

HAWK is drawing attention after reporting record third-quarter revenue and raising its full-year outlook, with traders also highlighting international growth, contract demand, and plans for lower-cost satellites. The community reaction is broadly bullish on the results and rally, though claims of institutional accumulation and further upside remain speculative.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Kura Oncology (KURA) Reports Q3 Loss, Beats Revenue Estimates

Kura Oncology (KURA) delivered earnings and revenue surprises of +6.02% and +2.87%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Septerna, Inc. (SEPN) Reports Q3 Loss, Lags Revenue Estimates

Septerna, Inc. (SEPN) delivered earnings and revenue surprises of -3.64% and -19.52%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Kura Oncology (KURA) Loses 35.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Kura Oncology (KURA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Beats Revenue Estimates

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of +17.42% and +25.30%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Cytek Biosciences, Inc. (CTKB) Reports Q3 Loss, Tops Revenue Estimates

Cytek Biosciences (CTKB) delivered earnings and revenue surprises of +37.50% and +0.62%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Qiagen (QGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Qiagen (QGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Kura Oncology (KURA) Report Negative Q3 Earnings? What You Should Know

Kura Oncology (KURA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

This Toll Brothers Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Analysts initiated bullish coverage on Vita Coco, Toll Brothers, Civeo, Teva and Kura Oncology, with price targets of $70, $159, $42, $55 and $30.read more...

Kura Oncology Q2 2026 Earnings Call Transcript

On Wednesday, Kura Oncology (NASDAQ:KURA) discussed second-quarter financial results during its earnings call. The full transcript is provided below.
Benzinga APIs provide real-time access to earnings call transcriptsread more...

Kura Oncology Pivots Diabetes Strategy Into $50 Million Subsidiary

Kura Oncology launches Caspian Therapeutics with $50 million financing to advance menin inhibitor for diabetes and cardiometabolic diseases.read more...

• Reported GAAP EPS of -$0.78 up 8.24% YoY
• Reported revenue of $22.84M up 10.07% YoY
• Kura Oncology believes cash, cash equivalents and short-term investments will fund its operating plan into 2028; anticipated $180M in Kyowa milestones and conditional financing are expected to provide resources beyond KOMET-017 topline results in 2028.

Kura Oncology reported a quarterly loss and operating cash use, disclosed asset-secured debt and future U.S. sales-based royalty payments, and competes in AML with KOMZIFTI approved for a limited indication.

Kura Oncology reported KOMZIFTI revenue and parity coverage for more than 95% of U.S. covered lives, continued enrollment in both KOMET-017 trials, and darlifarnib-cabozantinib ORRs of 33% to 50% with 13-month median PFS.

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Kura Oncology Inc

KURA Stock Hits Fresh 52-Week High As CEO Buys More Shares — Retail Wonders If Wilson Is Following Moderna CEO’s Playbook

Equity

Extremely Bullish Sentiment

<ul class="summary-bullets"><li>Over eight days, Wilson has invested around $2.35 million in company stock.</li><li>The buying comes shortly after Kura reported second-quarter results showing early commercial traction for its approved drug KOMZIFTI.</li><li>A retail trader asked whether KURA stock is following the playbook of Moderna CEO Stéphane Bancel, who bought shares in March at a significant discount to the current price.</li></ul><p>Shares of Kura Oncology (KURA) closed 10% higher on Tuesday after hitting a fresh 52-week high above $13.90, as investors reacted to the company’s CEO buying more shares of the company.</p><p>The stock clocked its best day on Tuesday since May.</p><h2 class="st-heading-2">CEO Adds To Stake In Open-Market Buys</h2><p>According to an SEC filing, Kura President and CEO Troy Edward Wilson bought 100,000 shares of common stock on August 24. The shares were acquired in multiple trades at prices ranging from $11.47 to $12.85, for a weighted average of $12.39—about $1.24 million in total. The shares are held through a trust.</p><p>This follows a similar purchase of an additional 100,000 shares on August 17 at a weighted-average price of $11.12. Over eight days, Wilson has invested around $2.35 million in company stock, a move widely seen as a vote of confidence.</p><h2 class="st-heading-2">Strong Start For Commercial Product</h2><p>The buying comes shortly after Kura reported second-quarter results showing early commercial traction for its approved drug KOMZIFTI. The therapy generated $9.1 million in net product sales, up 57% from the prior quarter. It has already captured a majority share of new patients in its approved use for certain relapsed or refractory blood cancers.</p><p>The company ended June with $519 million in cash and investments, plus expected partnership payments that will support operations for years to come.</p><h2 class="st-heading-2">Upcoming Data Readouts In Focus</h2><p>In the near term, attention is now on several clinical updates expected in the second half of 2026. These include longer-term results from combination studies of KOMZIFTI with standard treatments in newly diagnosed patients, initial data from pairings with other targeted therapies, and exploratory findings in additional patient groups. Progress on a second candidate, darlifarnib, in solid tumors also continues.</p><h2 class="st-heading-2">How Did Retail Traders React?</h2><p>On Stocktwits, retail sentiment around KURA stock remained ‘bullish’ over the past 24 hours, while message volume was ‘extremely high.’</p><p>A Stocktwits user expressed optimism that the stock would eventually break resistance levels and explode.</p><p><stembedurl>https://stocktwits.com/AdiDasRom/message/662823669</stembedurl></p><p>Another asked whether the Kura CEO is following Moderna CEO’s playbook. Moderna (MRNA) CEO Stéphane Bancel last bought shares of the company on the open market in March for a total value of about $5 million. He bought the shares at a weighted average price of $31.22, and MRNA shares are currently trading at about $159.</p><p><stembedurl>https://stocktwits.com/Jtlo/message/662808425</stembedurl></p><p>A third user applauded the CEO for defending KURA’s stock price.</p><p><stembedurl>https://stocktwits.com/DCZ/message/662797244</stembedurl></p><p><a href="https://stocktwits.com/symbol/KURA">KURA stock</a> has gained 31% year-to-date.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-s-cybertruck-base-version-hits-74-990-nearly-2-x-its-2019-promised-price/cZYkCspRJoL">Tesla’s Cybertruck Base Version Hits $74,990 — Nearly 2X Its 2019 Promised Price</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the logo of Kura Oncology is displayed on the screen of a smart tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

According to a filing with the SEC, Kura President and CEO Troy Edward Wilson bought 100,000 shares of common stock on August 24 for about $1.24 million in total.

Vanguard Total Stock Market ETF

SPDR S&P Biotech ETF

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '26	-$0.83	--	--	N/A
Q3 '26	-$0.82	-$0.78	4.84%	BEAT
Q2 '26	-$0.88	-$0.77	12.23%	BEAT
Q1 '26	-$0.83	-$0.83	0.54%	BEAT
Q4 '25	-$0.64	-$0.92	-43.98%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

KURA Earnings

Latest Earnings Results: Q3 '26

Historical Earnings